Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept Therapeutics' ALS drug fails in mid-stage trial
05:27pm, Wednesday, 11'th Dec 2024
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
04:05pm, Wednesday, 11'th Dec 2024
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
10:50am, Wednesday, 11'th Dec 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 09'th Dec 2024
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
10:55am, Friday, 06'th Dec 2024
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
09:51am, Friday, 06'th Dec 2024
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?
12:37pm, Friday, 29'th Nov 2024
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics: A Most Promising And Compelling Biotech
08:00am, Wednesday, 27'th Nov 2024
Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust f
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
10:56am, Monday, 25'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
12:36pm, Friday, 22'nd Nov 2024
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
3 Reasons Growth Investors Will Love Corcept (CORT)
01:46pm, Thursday, 21'st Nov 2024
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
10:55am, Wednesday, 20'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positi
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable
09:50am, Wednesday, 20'th Nov 2024
Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
08:51am, Monday, 11'th Nov 2024
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
08:21am, Friday, 08'th Nov 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
